R
Robert L. Martuza
Researcher at Harvard University
Publications - 264
Citations - 30135
Robert L. Martuza is an academic researcher from Harvard University. The author has contributed to research in topics: Oncolytic virus & Herpes simplex virus. The author has an hindex of 79, co-authored 263 publications receiving 27228 citations. Previous affiliations of Robert L. Martuza include Georgetown University Medical Center & House Ear Institute.
Papers
More filters
Journal ArticleDOI
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel,Itay Tirosh,John J. Trombetta,Alex K. Shalek,Shawn M. Gillespie,Hiroaki Wakimoto,Daniel P. Cahill,Brian V. Nahed,William T. Curry,Robert L. Martuza,David N. Louis,Orit Rozenblatt-Rosen,Mario L. Suvà,Mario L. Suvà,Aviv Regev,Aviv Regev,Aviv Regev,Bradley E. Bernstein,Bradley E. Bernstein,Bradley E. Bernstein +19 more
TL;DR: The genome sequence of single cells isolated from brain glioblastomas was examined, which revealed shared chromosomal changes but also extensive transcription variation, including genes related to signaling, which represent potential therapeutic targets.
Journal ArticleDOI
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor
James A. Trofatter,Mia MacCollin,Joni L. Rutter,Jill R. Murrell,Mabel P. Duyao,Dilys M. Parry,Roswell Eldridge,Nikolai Kley,Anil G. Menon,K Pulaski,Volker H. Haase,Christine Ambrose,David J. Munroe,Catherine Bove,Jonathan L. Haines,Robert L. Martuza,Marcy E. MacDonald,Bernd R. Seizinger,M. Priscilla Short,Alan Buckler,James F. Gusella +20 more
TL;DR: A candidate gene for the NF2 tumor suppressor that has suffered nonoverlapping deletions in DNA from two independent NF2 families and alterations in meningiomas from two unrelated NF2 patients is identified.
Journal ArticleDOI
Experimental therapy of human glioma by means of a genetically engineered virus mutant
TL;DR: A thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas and merit further evaluation as novel antineoplastic agents.
Journal ArticleDOI
Meningioma: analysis of recurrence and progression following neurosurgical resection
TL;DR: The rates of survival, tumor recurrence, and tumor progression were analyzed in 225 patients with meningioma who underwent surgery as the only treatment modality between 1962 and 1980, and there was no difference in the recurrence/progression rates according to the patients' age or sex, or the duration of symptoms.
Journal ArticleDOI
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
James M. Markert,M D Medlock,Samuel D. Rabkin,George Yancey Gillespie,Tomoki Todo,William D. Hunter,Cheryl A. Palmer,F Feigenbaum,C Tornatore,F Tufaro,Robert L. Martuza +10 more
TL;DR: Radiographic and neuropathologic evidence suggestive of anti-tumor activity and long-term presence of viral DNA in some cases is found, and no toxicity or serious adverse events could unequivocally be ascribed to G207.